WHO Sounds Concern Over Severe Lack of Obesity Injections
Fewer than 10% of patients that would benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it publishes its first recommendations on the therapies.
With over a billion individuals worldwide now classified as obese, it is urging increased and just access to this class of drugs.
Based on forecasts, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The latest guidance recognises that excess weight is a lifelong illness that can be addressed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to widespread availability to the injections that can aid individuals in losing significant body mass, notes the agency.
GLP-1 Therapy Supply Crisis
Despite the present best projected scenario, the supply of such drugs could only cover about 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The guideline urges governments and firms to widen access, through strategies including patent sharing.
The intellectual property rights on the active ingredient – the core component of a leading brand – is due to expire in a number of countries in 2026.
The Way Obesity Jabs Function
These medications mimick a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so people reduce food intake.
Individuals usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Research points to people may put most of the weight back on a year later of halting the treatment, as their typical hunger return.
Being carrying excess weight elevates your likelihood for contracting diseases, including diabetes, heart disease, brain attack, and some malignancies.
Excess weight impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the health agency.
